Cover Image
市場調查報告書

Marina Biotech, Inc.的產品平台分析

Marina Biotech, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224588
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Marina Biotech, Inc.的產品平台分析 Marina Biotech, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月29日 內容資訊: 英文 32 Pages
簡介

本報告提供Marina Biotech, Inc.的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,以及暫停中的計劃等資訊。

Marina Biotech, Inc.的基本資料

Marina Biotech, Inc.概要

  • 主要資訊
  • 企業資料

Marina Biotech, Inc.:R&D概要

  • 主要的治療範圍

Marina Biotech, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Marina Biotech, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Marina Biotech, Inc.:藥物簡介

  • CEQ-508
  • CEQ-501
  • MDR-09521
  • 癌症治療用阻礙MicroRNA-122的RNAioligo核苷酸
  • 裘馨氏肌肉萎縮症治療用RNAioligo核苷酸
  • 筋肉僵硬性dystrophy治療用RNAioligo核苷酸
  • 惡性腹水治療用阻礙PLK1的RNAioligo核苷酸

Marina Biotech, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Marina Biotech, Inc.:最近的開發平台趨勢

Marina Biotech, Inc.:暫停中的計劃

Marina Biotech, Inc.:企業發表

Marina Biotech, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07205CDB

Summary

Global Markets Direct's, 'Marina Biotech, Inc. - Product Pipeline Review - 2015', provides an overview of the Marina Biotech, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Marina Biotech, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Marina Biotech, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Marina Biotech, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Marina Biotech, Inc.'s pipeline products

Reasons to buy

  • Evaluate Marina Biotech, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Marina Biotech, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Marina Biotech, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Marina Biotech, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Marina Biotech, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Marina Biotech, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Marina Biotech, Inc. Snapshot
    • Marina Biotech, Inc. Overview
    • Key Information
    • Key Facts
  • Marina Biotech, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Marina Biotech, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Marina Biotech, Inc. - Pipeline Products Glance
    • Marina Biotech, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Marina Biotech, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Marina Biotech, Inc. - Drug Profiles
    • CEQ-508
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CEQ-501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MDR-09521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide to Inhibit MicroRNA-122 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Myotonic Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides to Inhibit PLK1 for Malignant Ascites
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Marina Biotech, Inc. - Pipeline Analysis
    • Marina Biotech, Inc. - Pipeline Products by Target
    • Marina Biotech, Inc. - Pipeline Products by Route of Administration
    • Marina Biotech, Inc. - Pipeline Products by Molecule Type
    • Marina Biotech, Inc. - Pipeline Products by Mechanism of Action
  • Marina Biotech, Inc. - Recent Pipeline Updates
  • Marina Biotech, Inc. - Dormant Projects
  • Marina Biotech, Inc. - Company Statement
  • Marina Biotech, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Marina Biotech, Inc., Key Information
  • Marina Biotech, Inc., Key Facts
  • Marina Biotech, Inc. - Pipeline by Indication, 2015
  • Marina Biotech, Inc. - Pipeline by Stage of Development, 2015
  • Marina Biotech, Inc. - Monotherapy Products in Pipeline, 2015
  • Marina Biotech, Inc. - Partnered Products in Pipeline, 2015
  • Marina Biotech, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Marina Biotech, Inc. - Phase I, 2015
  • Marina Biotech, Inc. - Preclinical, 2015
  • Marina Biotech, Inc. - Pipeline by Target, 2015
  • Marina Biotech, Inc. - Pipeline by Route of Administration, 2015
  • Marina Biotech, Inc. - Pipeline by Molecule Type, 2015
  • Marina Biotech, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Marina Biotech, Inc. - Recent Pipeline Updates, 2015
  • Marina Biotech, Inc. - Dormant Developmental Projects,2015
  • Marina Biotech, Inc., Subsidiaries

List of Figures

  • Marina Biotech, Inc. - Pipeline by Top 10 Indication, 2015
  • Marina Biotech, Inc. - Pipeline by Stage of Development, 2015
  • Marina Biotech, Inc. - Monotherapy Products in Pipeline, 2015
  • Marina Biotech, Inc. - Partnered Products in Pipeline, 2015
  • Marina Biotech, Inc. - Pipeline by Top 10 Target, 2015
  • Marina Biotech, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Marina Biotech, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Marina Biotech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top